Emma Walmsley - GlaxoSmithKline PLC CEO Director
| GSK Stock | 1,340 3.50 0.26% |
Insider
Emma Walmsley is CEO Director of GlaxoSmithKline PLC
| Age | 55 |
| Address | 980 Great West Road, Brentford, United Kingdom, TW8 9GS |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GlaxoSmithKline PLC Management Efficiency
The company has return on total asset (ROA) of 0.0724 % which means that it generated a profit of $0.0724 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2185 %, meaning that it generated $0.2185 on every $100 dollars invested by stockholders. GlaxoSmithKline PLC's management efficiency ratios could be used to measure how well GlaxoSmithKline PLC manages its routine affairs as well as how well it operates its assets and liabilities. At present, GlaxoSmithKline PLC's Other Current Assets are projected to decrease significantly based on the last few years of reporting.Similar Executives
| Found 8 records | INSIDER Age | ||
| Ashwini Tewari | State Bank of | 57 | |
| Mahindra Kumar | State Bank of | N/A | |
| Challa Setty | State Bank of | 59 | |
| Charanjit Attra | State Bank of | N/A | |
| Siddhartha Sengupta | State Bank of | 65 | |
| Prabodh Parikh | State Bank of | N/A | |
| Swaminathan Janakiraman | State Bank of | 60 | |
| Sureddi Rao | State Bank of | N/A | |
Management Performance
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0724 |
GlaxoSmithKline PLC Leadership Team
Elected by the shareholders, the GlaxoSmithKline PLC's board of directors comprises two types of representatives: GlaxoSmithKline PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline PLC's management team and ensure that shareholders' interests are well served. GlaxoSmithKline PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie ACA, CFO Director | ||
| Luke Miels, Chief Officer | ||
| Emma Walmsley, CEO Director | ||
| Sally Jackson, Senior Office | ||
| James Ford, Senior Compliance | ||
| CA BSc, President Development | ||
| Philip Thomson, President Affairs | ||
| Tony Wood, Chief Officer | ||
| David Redfern, Chief Officer | ||
| Diana Conrad, Chief Officer | ||
| Iain Mackay, CFO Director | ||
| Shobie Ramakrishnan, Chief Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Julie Brown, Chief Officer |
GlaxoSmithKline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlaxoSmithKline PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0724 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 67.69 B | ||||
| Shares Outstanding | 4.08 B | ||||
| Shares Owned By Insiders | 1.61 % | ||||
| Shares Owned By Institutions | 45.15 % | ||||
| Price To Book | 3.92 X | ||||
| Price To Sales | 1.75 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in GlaxoSmithKline Stock
GlaxoSmithKline PLC financial ratios help investors to determine whether GlaxoSmithKline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GlaxoSmithKline with respect to the benefits of owning GlaxoSmithKline PLC security.